ozempic or retatrutide vs. semaglutide: A head-to-head comparison Retatrutide for weight loss: Study

doi: 10.1056/NEJMoa1212914 242 PownallHJSchwartzAVBrayGABerkowitzRILewisCEBoykoEJet al

By potentiating GABA signaling, DSIP supports the neural quieting necessary for sleep onset and maintenance

#PRESS: The Committee for Medicinal Products for Human Use (CHMP) has recommended approval of our GLP-1 pill for the treatment of obesity in the European Union (EU), making it one step closer to becoming available for people with overweight or obesity in the EU

Recent Findings Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D